Antipodes Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Antipodes Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,234	Closed	-$67.3K	–	153
2026 Q1	$67.3K	Buy	2,234 +148	+7%	+$4.76K	﹤0.01%	103
2025 Q4	$65.1K	Buy	+2,086	New	+$51.4K	﹤0.01%	102

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Antipodes Partners's TEVA Position: Q2 2026 in Review

Antipodes Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2026, closing a stake of 2,234 shares — an estimated $67.3K sold.

Antipodes Partners first reported a position in TEVA in Q4 2025 and held it in 2 quarters. The position peaked at $67.3K in Q1 2026. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Antipodes Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2026 after selling out during the quarter.
Antipodes Partners sold 2,234 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $67.3K.
Antipodes Partners first reported a position in Teva Pharmaceutical Industries Limited in Q4 2025 and held it in 2 quarters.
Antipodes Partners's Teva Pharmaceutical Industries Limited position peaked at $67.3K in Q1 2026.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.